These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22915655)

  • 1. Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer.
    Heuckmann JM; Rauh D; Thomas RK
    J Clin Oncol; 2012 Sep; 30(27):3417-20. PubMed ID: 22915655
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR inhibitors: what have we learned from the treatment of lung cancer?
    Giaccone G; Rodriguez JA
    Nat Clin Pract Oncol; 2005 Nov; 2(11):554-61. PubMed ID: 16270096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib.
    Schwab R; Pinter F; Moldavy J; Papay J; Strausz J; Kopper L; Keri G; Pap A; Petak I; Oreskovich K; Mangel L
    J Clin Oncol; 2005 Oct; 23(30):7736-8. PubMed ID: 16234532
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Jänne PA; Johnson BE
    Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
    Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA
    Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor mutations in lung cancer.
    Sharma SV; Bell DW; Settleman J; Haber DA
    Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.
    Kotsakis A; Georgoulias V
    Expert Opin Pharmacother; 2010 Oct; 11(14):2363-89. PubMed ID: 20586711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK
    Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
    Oxnard GR
    Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation.
    Lee JK; Kim TM; Koh Y; Lee SH; Kim DW; Jeon YK; Chung DH; Yang SC; Kim YT; Kim YW; Heo DS; Bang YJ
    Lung Cancer; 2012 Aug; 77(2):460-3. PubMed ID: 22622260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Next Wave of EGFR Tyrosine Kinase Inhibitors Enter the Clinic.
    Politi K; Ayeni D; Lynch T
    Cancer Cell; 2015 Jun; 27(6):751-3. PubMed ID: 26058074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 14. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
    [No Abstract]   [Full Text] [Related]  

  • 15. Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.
    Ansén S; Bangard C; Querings S; Gabler F; Scheffler M; Seidel D; Saal B; Zander T; Nogová L; Töpelt K; Markert E; Stoelben E; Ernestus K; Thomas RK; Wolf J
    J Thorac Oncol; 2010 Mar; 5(3):407-9. PubMed ID: 20186030
    [No Abstract]   [Full Text] [Related]  

  • 16. Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations.
    Moran T; Sequist LV
    J Clin Oncol; 2012 Sep; 30(27):3330-6. PubMed ID: 22753908
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular on/off switch.
    Milton DT; Riely GJ; Pao W; Miller VA; Kris MG; Heelan RT
    J Clin Oncol; 2006 Oct; 24(30):4940-2. PubMed ID: 17050880
    [No Abstract]   [Full Text] [Related]  

  • 18. Does the addition of vascular endothelial growth factor inhibitors to epidermal growth factor receptor-tyrosine kinase inhibitor overcome T790M acquired resistance?
    Hata A; Kaji R; Fujita S; Katakami N
    J Thorac Oncol; 2011 Feb; 6(2):404. PubMed ID: 21252723
    [No Abstract]   [Full Text] [Related]  

  • 19. [I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].
    Urata Y; Satouchi M
    Gan To Kagaku Ryoho; 2015 Aug; 42(8):931-4. PubMed ID: 26353389
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of third-generation epithelial growth factor receptor inhibitors in non-small cell lung cancer.
    Sequist LV
    Clin Adv Hematol Oncol; 2015 Mar; 13(3):147-9. PubMed ID: 26352419
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.